ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

Dimethylformamide → N-[5-(4-[2-(2,2,2-trifluoroethyl)guanidino]pyrimid-2-yl)pentyl]-3-(imidazol-4-yl)propionamide bis maleate hemihydrate

HRID 2413199
ノート
印刷プレビュー

反応式

HRID 2413199 の反応式
ClC([O:4][CH2:5][CH3:6])=[O:3].[NH:7]1[CH:11]=[C:10]([CH2:12][CH2:13][C:14]([OH:16])=[O:15])[N:9]=[CH:8]1.C(N(CC)CC)C.[F:24][C:25]([F:44])([F:43])[CH2:26][N:27]=[C:28]([NH2:42])[NH:29][C:30]1[CH:35]=[CH:34][N:33]=[C:32]([CH2:36][CH2:37][CH2:38][CH2:39][CH2:40][NH2:41])[N:31]=1.CN([CH:48]=[O:49])C>>[OH2:3].[C:5]([OH:4])(=[O:49])/[CH:6]=[CH:13]\[C:14]([OH:16])=[O:15].[C:48]([OH:49])(=[O:3])/[CH:12]=[CH:13]\[C:14]([OH:16])=[O:15].[F:44][C:25]([F:24])([F:43])[CH2:26][N:27]=[C:28]([NH2:42])[NH:29][C:30]1[CH:35]=[CH:34][N:33]=[C:32]([CH2:36][CH2:37][CH2:38][CH2:39][CH2:40][NH:41][C:14](=[O:16])[CH2:13][CH2:12][C:10]2[N:9]=[CH:8][NH:7][CH:11]=2)[N:31]=1.[F:44][C:25]([F:24])([F:43])[CH2:26][N:27]=[C:28]([NH2:42])[NH:29][C:30]1[CH:35]=[CH:34][N:33]=[C:32]([CH2:36][CH2:37][CH2:38][CH2:39][CH2:40][NH:41][C:14](=[O:16])[CH2:13][CH2:12][C:10]2[N:9]=[CH:8][NH:7][CH:11]=2)[N:31]=1.[C:5]([OH:4])(=[O:49])/[CH:6]=[CH:13]\[C:14]([OH:16])=[O:15].[C:5]([OH:4])(=[O:49])/[CH:6]=[CH:13]\[C:14]([OH:16])=[O:15]
参加物実験手順後処理出典と根拠反応ノート

参加物

6

反応物 5

HCID 6228Dimethylformamide2 回HCID 8471TriethylamineHCID 10928Ethyl chloroformateHCID 202086774-[2-(2,2,2-Trifluoroethyl)guanidino]-2-(5-aminopentyl)pyrimidineHCID 178525356HCID 178525356、化合物

生成物 1

HCID 178512205
N-[5-(4-[2-(2,2,2-trifluoroethyl)guanidino]pyrimid-2-yl)pentyl]-3-(imidazol-4-yl)propionamide bis maleate hemihydrate

実験手順

Ethyl chloroformate (0.14 ml.) was added to a stirred mixture of 3-(imidazol-4-yl)propionic acid (0.3 g.) and triethylamine (2 ml.) in DMF (5 ml.) at 0° and the mixture stirred at 0° for 0.5 hours. 4-[2-(2,2,2-Trifluoroethyl)guanidino]-2-(5-aminopentyl)pyrimidine (0.3 g.) in DMF (2 ml.) was added to the mixture and stirring was continued at room temperature for 16 hours. The mixture was evaporated and the residue partitioned between EtOAc and 2 N aqueous HCl. The acid layer was basified with 11 N aqueous NaOH, extracted with EtOAc, dried (MgSO4) and evaporated to dryness. The residual gum was dissolved in EtOAc and treated with excess of a solution of maleic acid in EtOAc. The resulting solid was filtered and recrystallised from EtOH/EtOAc to give N-[5-(4-[2-(2,2,2-trifluoroethyl)guanidino]pyrimid-2-yl)pentyl]-3-(imidazol-4-yl)propionamide bis maleate hemihydrate (containing 0.5 EtOH of crystallisation) (0.2 g.), m.p. 136°-141° (decomp.).

後処理

  1. stirringstirring
  2. waitwas continued at room temperature for 16 hours
  3. customThe mixture was evaporated
  4. customthe residue partitioned between EtOAc and 2 N aqueous HCl
  5. extractionextracted with EtOAc
  6. dry with materialdried (MgSO4)
  7. customevaporated to dryness
  8. dissolutionThe residual gum was dissolved in EtOAc
  9. additiontreated with excess of a solution of maleic acid in EtOAc
  10. filtrationThe resulting solid was filtered
  11. customrecrystallised from EtOH/EtOAc

出典と根拠

ORDレコード
ord-bd2c05f0aa0c4aa8b5265f01aa05792e
出典データセット
uspto-grants-1985_01
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US04496571

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート